{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    7,
    15,
    35,
    36,
    39,
    40,
    43
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Schedule of Activities Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "2",
        "sectionTitle": "Schedule of Activities",
        "description": "Reference to the timing and details of study procedures."
      },
      {
        "id": "ref_2",
        "name": "Clinical Laboratory Tests Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 2",
        "sectionTitle": "Clinical Laboratory Tests",
        "description": "Reference to the list of laboratory tests performed for the study."
      },
      {
        "id": "ref_3",
        "name": "Blood Sampling Summary Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 5",
        "sectionTitle": "Blood Sampling Summary",
        "description": "Reference to the maximum number and volume of invasive samples."
      },
      {
        "id": "ref_4",
        "name": "Efficacy Assessment Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "9.2.3",
        "sectionTitle": "Post Glucagon Administration",
        "description": "Reference to plasma glucose measurement procedures for efficacy."
      },
      {
        "id": "ref_5",
        "name": "Edinburgh Hypoglycemia Scale Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 7",
        "sectionTitle": "Edinburgh Hypoglycemia Scale",
        "description": "Reference to the self-reported assessment tool for hypoglycemia symptoms."
      },
      {
        "id": "ref_6",
        "name": "Clarke Hypoglycemia Awareness Survey Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 8",
        "sectionTitle": "Clarke Hypoglycemia Awareness Survey",
        "description": "Reference to the tool for capturing hypoglycemia awareness."
      },
      {
        "id": "ref_7",
        "name": "Treatment Details Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "7",
        "sectionTitle": "Treatment",
        "description": "Reference for details regarding treatments administered."
      },
      {
        "id": "ref_8",
        "name": "Nasal Score Questionnaire Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 6",
        "sectionTitle": "Nasal and Non-nasal Score Questionnaire",
        "description": "Reference to the questionnaire used if a patient sneezes after administration."
      },
      {
        "id": "ref_9",
        "name": "Hepatic Monitoring Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "Appendix 4",
        "sectionTitle": "Hepatic Monitoring Tests for Treatment-emergent Abnormality",
        "description": "Reference to liver tests required for elevated ALT, ALP, or TBL."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "TE ADA: Treatment-emergent anti-drug antibodies.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_2",
        "text": "Patients do not need to fast for samples at screening or follow-up. At Periods 1 and 2, samples should be collected from patients who have fasted at least 8 hours before any study procedures.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_3",
        "text": "Serum pregnancy test will be performed at screening. Urine pregnancy test will be performed at every admission period and follow-up visit if applicable.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Schedule of Activities",
        "pageNumber": 15
      },
      {
        "id": "annot_4",
        "text": "This document may contain protected personal data and/or commercially confidential information exempt from public disclosure.",
        "annotationType": "Note",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Confidential Information",
        "pageNumber": 2
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "I8R-JE-IGBJ(a)",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2017-12-05",
        "description": "Clinical Pharmacology Protocol Amendment (a) electronically signed and approved by Lilly.",
        "amendmentNumber": "(a)"
      }
    ],
    "summary": {
      "referenceCount": 9,
      "annotationCount": 4,
      "versionCount": 1
    }
  }
}